Cooper Q3 2021 Earnings Report
Key Takeaways
CooperCompanies announced a strong third quarter with revenue increasing by 32% year-over-year to $763.4 million. Both CooperVision and CooperSurgical experienced record revenues, contributing to record earnings and robust free cash flow. GAAP diluted earnings per share reached $12.37, while non-GAAP diluted earnings per share was $3.41, a 50% increase from the previous year.
Revenue increased 32% year-over-year to $763.4 million.
CooperVision (CVI) revenue was up 24% to $557.5 million.
CooperSurgical (CSI) revenue was up 60% to $205.9 million.
Non-GAAP diluted earnings per share was $3.41, up 50% from last year's third quarter.
Cooper
Cooper
Cooper Revenue by Segment
Cooper Revenue by Geographic Location
Forward Guidance
CooperCompanies updated its fiscal year 2021 financial guidance, while still viewing resurgences as a significant risk factor to our outlook.
Positive Outlook
- Fiscal 2021 total revenue $2,893- $2,923 million (16% to 18% constant currency)
- CVI revenue $2,127 - $2,147 million (12% to 13% constant currency)
- CSI revenue $766 - $776 million (29% to 31% constant currency)
- Fiscal 2021 non-GAAP diluted EPS $13.20 - $13.40
- Fiscal fourth quarter 2021 total revenue $730 - $760 million (7% to 11% constant currency)
Challenges Ahead
- CVI revenue $540 - $560 million (6% to 10% constant currency)
- CSI revenue $190 - $200 million (9% to 14% constant currency)
- Fiscal fourth quarter 2021 non-GAAP diluted EPS $3.24 - $3.44
- The Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses
- resurgences as a significant risk factor to our outlook
Revenue & Expenses
Visualization of income flow from segment revenue to net income